732 related articles for article (PubMed ID: 26057769)
21. Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders.
Ong WY; Shalini SM; Costantino L
Curr Med Chem; 2014; 21(37):4247-56. PubMed ID: 25039773
[TBL] [Abstract][Full Text] [Related]
22. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
[TBL] [Abstract][Full Text] [Related]
23. Versatile Nanoparticulate Systems as a Prosperous Platform for Targeted Nose-Brain Drug Delivery.
Taha E; Shetta A; Nour SA; Naguib MJ; Mamdouh W
Mol Pharm; 2024 Mar; 21(3):999-1014. PubMed ID: 38329097
[TBL] [Abstract][Full Text] [Related]
24. From nose to brain: understanding transport capacity and transport rate of drugs.
Wu H; Hu K; Jiang X
Expert Opin Drug Deliv; 2008 Oct; 5(10):1159-68. PubMed ID: 18817519
[TBL] [Abstract][Full Text] [Related]
25. Improving brain drug targeting through exploitation of the nose-to-brain route: a physiological and pharmacokinetic perspective.
Badhan RK; Kaur M; Lungare S; Obuobi S
Curr Drug Deliv; 2014; 11(4):458-71. PubMed ID: 24655046
[TBL] [Abstract][Full Text] [Related]
26. Nose-to-brain drug delivery for the treatment of CNS disease: New development and strategies.
Du L; Chen L; Liu F; Wang W; Huang H
Int Rev Neurobiol; 2023; 171():255-297. PubMed ID: 37783558
[TBL] [Abstract][Full Text] [Related]
27. Quantitative analysis of drug delivery to the brain via nasal route.
Kozlovskaya L; Abou-Kaoud M; Stepensky D
J Control Release; 2014 Sep; 189():133-40. PubMed ID: 24997277
[TBL] [Abstract][Full Text] [Related]
28. Recent patents review on intranasal administration for CNS drug delivery.
Jogani V; Jinturkar K; Vyas T; Misra A
Recent Pat Drug Deliv Formul; 2008; 2(1):25-40. PubMed ID: 19075895
[TBL] [Abstract][Full Text] [Related]
29. Current Strategies for Brain Drug Delivery.
Dong X
Theranostics; 2018; 8(6):1481-1493. PubMed ID: 29556336
[TBL] [Abstract][Full Text] [Related]
30. Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies.
Pires PC; Santos AO
J Control Release; 2018 Jan; 270():89-100. PubMed ID: 29199063
[TBL] [Abstract][Full Text] [Related]
31. Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease.
Saha P; Kathuria H; Pandey MM
J Control Release; 2023 Jun; 358():293-318. PubMed ID: 37061193
[TBL] [Abstract][Full Text] [Related]
32. Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method.
Md S; Haque S; Fazil M; Kumar M; Baboota S; Sahni JK; Ali J
Expert Opin Drug Deliv; 2014 Jun; 11(6):827-42. PubMed ID: 24655115
[TBL] [Abstract][Full Text] [Related]
33. Intranasal delivery of biologics to the central nervous system.
Lochhead JJ; Thorne RG
Adv Drug Deliv Rev; 2012 May; 64(7):614-28. PubMed ID: 22119441
[TBL] [Abstract][Full Text] [Related]
34. Nasal-nanotechnology: revolution for efficient therapeutics delivery.
Kumar A; Pandey AN; Jain SK
Drug Deliv; 2016; 23(3):681-93. PubMed ID: 24901207
[TBL] [Abstract][Full Text] [Related]
35. Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration.
Shah B; Khunt D; Misra M; Padh H
Eur J Pharm Sci; 2016 Aug; 91():196-207. PubMed ID: 27174656
[TBL] [Abstract][Full Text] [Related]
36. Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration.
Wen Z; Yan Z; He R; Pang Z; Guo L; Qian Y; Jiang X; Fang L
Drug Deliv; 2011 Nov; 18(8):555-61. PubMed ID: 21812752
[TBL] [Abstract][Full Text] [Related]
37. Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases.
Fan Y; Chen M; Zhang J; Maincent P; Xia X; Wu W
Crit Rev Ther Drug Carrier Syst; 2018; 35(5):433-467. PubMed ID: 30317945
[TBL] [Abstract][Full Text] [Related]
38. Nanotechnological advances for the delivery of CNS therapeutics.
Wong HL; Wu XY; Bendayan R
Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
[TBL] [Abstract][Full Text] [Related]
39. Nasal drug administration: potential for targeted central nervous system delivery.
Graff CL; Pollack GM
J Pharm Sci; 2005 Jun; 94(6):1187-95. PubMed ID: 15858850
[TBL] [Abstract][Full Text] [Related]
40. Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection.
DeMarino C; Schwab A; Pleet M; Mathiesen A; Friedman J; El-Hage N; Kashanchi F
J Neuroimmune Pharmacol; 2017 Mar; 12(1):31-50. PubMed ID: 27372507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
